Skip to main content
. 2019 Sep 4;2019(9):CD005049. doi: 10.1002/14651858.CD005049.pub5

Byrne‐Quinn 1970.

Methods RCT
Double‐blind
Loss to follow‐up reported: yes
Participants Persistent AF (mean duration: 12 months). n = 74
Men: 53%
Age (mean): 54 (range 30–70) years
Structural heart disease: 80%. LAD: NS. LVEF: NS
Interventions Quinidine 1.2 g/day vs placebo
Method of AF cardioversion: electrical
Warfarin discretionary
Outcomes At 12 months:
Mortality
Proarrhythmia
Adverse effects
AF recurrence
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk No information given on the method employed to generate the random sequence.
Allocation concealment (selection bias) Unclear risk Participants "were randomly allocated to two groups". No details provided.
Blinding (performance bias and detection bias) 
 All outcomes Low risk Identical tablets. Participants and investigators blinded.
Incomplete outcome data (attrition bias) 
 All outcomes High risk High proportion of participants withdrawn, unbalanced between groups.
Selective reporting (reporting bias) Low risk All study's prespecified outcomes of interest were reported. All main outcomes expected were reported.
Other bias Low risk No other bias apparent.